Donald M. Mock
Researcher
Also affiliated: University of Iowa (1985–2012); Brooke Army Medical Center (1985); San Francisco General Hospital (1987); Arkansas Children's Hospital (1993–2004); The University of Texas at San Antonio Health Science Center (1983–1997); University of California, San Francisco (1980–1987); Hormel (United States) (1985); University of Arkansas Medical Center (2001–2014); University of Iowa Hospitals and Clinics (1986–2004); University of California System (1981); University of California San Diego (1985); Arkana Laboratories (2009); Arturo Michelena University (2014); Laboratoire de Biochimie (2012); Maine Medical Center (1998); Iowa City VA Medical Center (2004); Clinical Research Management (2005); Arkansas Department of Agriculture (2010–2012); Arkansas Department of Health (2010); The University of Texas at Austin (1975); The University of Texas Southwestern Medical Center (1975); Joint Base San Antonio (1985); The University of Texas Health Science Center at Houston (1975)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Donald M. Mock's research has focused on the study of biotin and its role in biological systems, particularly concerning red blood cells. His work has investigated how antibodies against biotin-labeled red blood cells can impact their survival after transfusion. Mock has a significant publication record, with over 331 publications and a citation count exceeding 5,500, contributing to his h-index of 41. He is recognized as a highly cited researcher. His collaborations include work with Svetlana V. Kyosseva at the University of Arkansas for Medical Sciences, with whom he has co-authored shared publications. Mock's recent activity indicates ongoing engagement in research, with publications in 2022.
Metrics
- h-index: 41
- Publications: 331
- Citations: 5,524
Selected Publications
-
Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival (2022)
-
Biotin (2022)
-
Target-mediated disposition population pharmacokinetics model of erythropoietin in premature neonates following multiple intravenous and subcutaneous dosing regimens (2019)
-
Overlooked Issues on Pharmacokinetics Data Interpretation of Protein Drugs—a Case Example of Erythropoietin (2018)
-
Development, validation, and potential applications of biotinylated red blood cells for posttransfusion kinetics and other physiological studies: evidenced‐based analysis and recommendations (2018)
-
In premature infants there is no decrease in 24‐hour posttransfusion allogeneic red blood cell recovery after 42 days of storage (2017)
-
Biotin: From Nutrition to Therapeutics (2017)
-
Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cell‐biotin dose (2017)
-
Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing (2017)
-
Estimation of adult and neonatal RBC lifespans in anemic neonates using RBCs labeled at several discrete biotin densities (2017)
-
A Novel Physiology-Based Mathematical Model to Estimate Red Blood Cell Lifespan in Different Human Age Groups (2016)
-
Clearance of stored red blood cells is not increased compared with fresh red blood cells in a human endotoxemia model (2016)
-
Models for the red blood cell lifespan (2016)
-
Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis (2015)
-
Autologous Infant and Allogeneic Adult Red Cells Demonstrate Similar Concurrent Post-Transfusion Survival in Very Low Birth Weight Neonates (2015)
Collaboration Network
Top Collaborators
- Biotin
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
- Antibodies against biotin‐labeled red blood cells can shorten <scp>posttransfusion</scp> survival
Similar Researchers
Based on overlapping research topics